Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
With the business potentially at an important milestone, we thought we'd take a closer look at GlycoMimetics, Inc.'s...
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript March 27, 2024 GlycoMimetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this time, […]
Q4 2023 GlycoMimetics Inc Earnings Call
GLYC Advances Clinical Programs Despite Reporting Expected Losses
ROCKVILLE, Md., March 27, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million.
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ROCKVILLE, Md., March 13, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET.
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
ROCKVILLE, Md., February 26, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET.
ROCKVILLE, Md., February 12, 2024--GlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 6, 2024 of a non-qualified stock option award to purchase an aggregate of 130,000 shares of the Company’s common stock to Shantha Tyavanagimatt, Ph.D., the Company’s new Senior Vice President, Technical Operations. The award was granted as an inducement equity award outside of the Company’s Amended